{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:50:48Z","timestamp":1768081848349,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cranio-Maxillofacial Surgery"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.jcms.2017.11.007","type":"journal-article","created":{"date-parts":[[2017,11,20]],"date-time":"2017-11-20T23:47:29Z","timestamp":1511221649000},"page":"230-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["In\u00a0vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2412-7594","authenticated-orcid":false,"given":"Filip","family":"Koneski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danica","family":"Popovic-Monevska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Icko","family":"Gjorgoski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jovanka","family":"Krajoska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mirjana","family":"Popovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilijana","family":"Muratovska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris","family":"Velickovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordana","family":"Petrushevska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir","family":"Popovski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcms.2017.11.007_bib5","first-page":"e229","article-title":"The cytotoxic effects of three different bisphosphonates in-vitro on human gingival fibroblasts, osteoblasts and osteogenic sarcoma cells","volume":"40","author":"A\u00e7il","year":"2012","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib1","doi-asserted-by":"crossref","first-page":"971","DOI":"10.14219\/jada.archive.2007.0294","article-title":"The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors","volume":"138","author":"Adornato","year":"2007","journal-title":"J\u00a0Am Dent Assoc"},{"key":"10.1016\/j.jcms.2017.11.007_bib2","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.joms.2008.01.038","article-title":"Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment","volume":"66","author":"Allen","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib4","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1359\/jbmr.090713","article-title":"Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs","volume":"25","author":"Allen","year":"2010","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib6","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.jcms.2013.11.005","article-title":"Zoledronic acid-related osteonecrosis of the jaws. Experimental model with dental extractions in rats","volume":"42","author":"Barba-Recreo","year":"2014","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1590\/0103-6440201302229","article-title":"Cytotoxic effects of zoledronic acid on human epithelial cells and gingival fibroblasts","volume":"24","author":"Basso","year":"2013","journal-title":"Braz Dent J"},{"key":"10.1016\/j.jcms.2017.11.007_bib8","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jcms.2017.11.007_bib9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.ijom.2012.04.020","article-title":"Use of platelet-rich plasma in the treatment of bisphosphonate-related osteonecrosis of the jaw","volume":"41","author":"Bocanegra-P\u00e9rez","year":"2012","journal-title":"Inter J Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib10","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1177\/009127002762491316","article-title":"Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases","volume":"42","author":"Chen","year":"2002","journal-title":"J\u00a0Clin Pharmacol"},{"key":"10.1016\/j.jcms.2017.11.007_bib11","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1016\/j.joms.2011.03.005","article-title":"Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts","volume":"69","author":"Cozin","year":"2011","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/bbrc.1997.7145","article-title":"Novel salvage pathway utilizing farnesol and geranylgeraniol for protein isoprenylation","volume":"237","author":"Crick","year":"1997","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jcms.2017.11.007_bib13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.oooo.2013.11.490","article-title":"Does an alkaline environment prevent the development of bisphosphonate-related osteonecrosis of the jaw? An experimental study in rats","volume":"117","author":"Dayisoylu","year":"2014","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.jcms.2017.11.007_bib14","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in\u00a0vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib15","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.2174\/138161210791034003","article-title":"Bisphosphonates as treatment of bone metastases","volume":"16","author":"Holen","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.jcms.2017.11.007_bib16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40902-015-0020-6","article-title":"Development of animal model for bisphosphonates-related osteonecrosis of the jaw (BRONJ)","volume":"37","author":"Jang","year":"2015","journal-title":"Maxillofac Plast Reconstr Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib17","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.joms.2008.01.026","article-title":"Inhibition of oral mucosal cell wound healing by bisphosphonates","volume":"66","author":"Landesberg","year":"2008","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib18","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1563\/1548-1336(2007)33[371:UOPPIT]2.0.CO;2","article-title":"Use of platelet-rich plasma in the management of oral biphosphonate-associated osteonecrosis of the jaw: a report of 2 cases","volume":"33","author":"Lee","year":"2007","journal-title":"J\u00a0Oral Implantol"},{"key":"10.1016\/j.jcms.2017.11.007_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1200\/JCO.2001.19.2.558","article-title":"Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials","volume":"19","author":"Major","year":"2001","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jcms.2017.11.007_bib21","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","article-title":"Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: a report of 32 cases","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jcms.2017.11.007_bib22","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00784-012-0800-7","article-title":"Oral mucosa produces cytokines and factors influencing osteoclast activity and endothelial cell proliferation, in patients with osteonecrosis of jaw after treatment with zoledronic acid","volume":"17","author":"Mozzati","year":"2013","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.jcms.2017.11.007_bib23","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1177\/0022034514564187","article-title":"Mevalonates restore zoledronic acid-induced osteoclastogenesis inhibition","volume":"94","author":"Nagaoka","year":"2015","journal-title":"J\u00a0Dent Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib24","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1016\/j.joms.2010.07.017","article-title":"Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism","volume":"68","author":"Otto","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.joms.2009.07.079","article-title":"Bisphosphonate-related osteonecrosis of the jaw: is pH the missing part in the pathogenesis puzzle?","volume":"68","author":"Otto","year":"2010","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib26","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.jcms.2015.03.014","article-title":"The influence of geranylgeraniol on human oral keratinocytes after bisphosphonate treatment: an in\u00a0vitro study","volume":"43","author":"Pabst","year":"2015","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib27","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.bone.2012.04.020","article-title":"Bisphosphonate related osteonecrosis of the jaw: a minipig large animal model","volume":"51","author":"Pautke","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.jcms.2017.11.007_bib28","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.archoralbio.2010.11.003","article-title":"Bisphosphonate effects on the behavior of oral epithelial cells and oral fibroblasts","volume":"56","author":"Ravosa","year":"2011","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.jcms.2017.11.007_bib29","doi-asserted-by":"crossref","first-page":"6222","DOI":"10.1158\/1078-0432.CCR-06-0843","article-title":"Molecular mechanisms of action of bisphosphonates: current status","volume":"12","author":"Roelofs","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib30","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u25002014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S8756-3282(99)00116-7","article-title":"Bisphosphonates: from the laboratory to the clinic and back again","volume":"25","author":"Russell","year":"1999","journal-title":"Bone"},{"key":"10.1016\/j.jcms.2017.11.007_bib32","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1600-0714.2012.01173.x","article-title":"Exposing human epithelial cells to zoledronic acid can mediate osteonecrosis of jaw: an in\u00a0vitro model","volume":"41","author":"Saracino","year":"2012","journal-title":"J\u00a0Oral Pathol Med"},{"key":"10.1016\/j.jcms.2017.11.007_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1365-2141.2008.07504.x","article-title":"Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis","volume":"144","author":"Scheper","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jcms.2017.11.007_bib34","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2008.04.013","article-title":"Bony changes in the jaws of rats treated with zoledronic acid and dexamethasone before dental extractions mimic bisphosphonate-related osteonecrosis in cancer patients","volume":"45","author":"Sonis","year":"2009","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jcms.2017.11.007_bib35","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.archoralbio.2012.11.010","article-title":"In\u00a0vitro cytotoxicity of zoledronate (nitrogen-containing bisphosphonate: NBP) and\/or etidronate (non-BP) in tumour cells and periodontal cells","volume":"58","author":"Tanaka","year":"2013","journal-title":"Arch Oral Biol"},{"key":"10.1016\/j.jcms.2017.11.007_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0765.2010.01306.x","article-title":"Effects of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6","volume":"46","author":"Tipton","year":"2011","journal-title":"J\u00a0Periodont Res"},{"key":"10.1016\/j.jcms.2017.11.007_bib37","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00784-009-0266-4","article-title":"Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cells","volume":"14","author":"Walter","year":"2010","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.jcms.2017.11.007_bib39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jcms.2016.10.015","article-title":"The starting point for bisphosphonate-related osteonecrosis of the jaw: alveolar bone or oral mucosa? A randomized, controlled experimental study","volume":"45","author":"Zandi","year":"2017","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcms.2015.12.010","article-title":"Introducing a protocol to create bisphosphonate-related osteonecrosis of the jaw in rat animal model","volume":"44","author":"Zandi","year":"2016","journal-title":"J\u00a0Craniomaxillofac Surg"},{"key":"10.1016\/j.jcms.2017.11.007_bib40","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.oraloncology.2010.12.003","article-title":"Geranylgeraniol\u2013a new potential therapeutic approach to bisphosphonate associated osteonecrosis of the jaw","volume":"47","author":"Ziebart","year":"2011","journal-title":"Oral Oncol"}],"container-title":["Journal of Cranio-Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518217303815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1010518217303815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:37:22Z","timestamp":1760884642000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1010518217303815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1010518217303815"],"URL":"https:\/\/doi.org\/10.1016\/j.jcms.2017.11.007","relation":{},"ISSN":["1010-5182"],"issn-type":[{"value":"1010-5182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In\u00a0vivo effects of geranylgeraniol on the development of bisphosphonate-related osteonecrosis of the jaws","name":"articletitle","label":"Article Title"},{"value":"Journal of Cranio-Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcms.2017.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}